What are Lipinski rules?
The Lipinski “Rule of 5” is a widely-used set of empirical criteria developed by Dr. Chris Lipinski at Pfizer that is used to help identify compounds that have pharmaceutical properties making them more likely to be successful clinical candidates. They were derived by looking at the properties of known drugs on the market (see [add link to Lipinski literature reference]). In general a compound that fails more than 2 of the 5 rules is unlikely to be suitable for clinical use (though there are a number of very high profile counter-examples). The “Lipinski Rule of Five” is called thus because the cutoffs for each of four parameters are all close to five or a multiple of five.
